Amphastar Pharmaceuticals, Inc. (AMPH)

NMS – Real Time Price. Currency in USD

17.50

-0.95 (-5.15%)

At close: May 12, 2026, 4:00 PM EDT

17.70

+0.20 (1.14%)

Pre-market: May 13, 2026, 4:20 AM EDT

08.05.2026

Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2026 Earnings Call Transcript

08.05.2026

Compared to Estimates, Amphastar (AMPH) Q1 Earnings: A Look at Key Metrics

Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

07.05.2026

Amphastar Pharmaceuticals (AMPH) Q1 Earnings Lag Estimates

Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.42 per share, missing the Zacks Consensus Estimate of $0.7 per share. This compares to earnings of $0.74 per share a year ago.

07.05.2026

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026

Net revenues of $171.2 million for the three months ended March 31, 2026 GAAP net income of $6.4 million, or $0.14 per share, for the first quarter Adjusted non-GAAP net income of $19.5 million, or $0.42 per share, for the first quarter Company to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, CA / ACCESS Newswire / May 7, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company"), a biopharmaceutical company focused on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, today reported results for the three months ended March 31, 2026.

06.05.2026

Amphastar Pharmaceuticals to Present at the 2026 Bank of America Health Care Conference

RANCHO CUCAMONGA, CA / ACCESS Newswire / May 6, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be presenting at the 2026 Bank of America Health Care Conference on Wednesday, May 13, 2026, at 3:00 pm PT. For access to the webcast, visit Amphastar Pharmaceuticals' website at http://ir.amphastar.com.

30.04.2026

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7, 2026

RANCHO CUCAMONGA, CA / ACCESS Newswire / April 30, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that the Company will release results for its first quarter of 2026, ended March 31, 2026, after the market closes on Thursday, May 7, 2026, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.

29.04.2026

AMPH vs. RDY: Which Stock Should Value Investors Buy Now?

Investors interested in stocks from the Medical - Generic Drugs sector have probably already heard of Amphastar Pharmaceuticals (AMPH) and Doctor Reddy's (RDY). But which of these two companies is the best option for those looking for undervalued stocks?

Videos

No Data

There is no data to display

Press releases

07.05.2026

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026

26.02.2026

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025

Net revenues of $183.1 million and $719.9 million, respectively, for the three months and fiscal year ended December 31, 2025 GAAP net income of $24.4 million, or $0.51 per share and $98.1 million, or $2.03 per share, respectively, for the fourth quarter and fiscal year Adjusted non-GAAP net income of $34.2 million, or $0.73 per share and $156.6 million, or $3.25 per share, respectively, for the fourth quarter and fiscal year Company to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, CA / ACCESS Newswire / February 26, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company"), a biopharmaceutical company focused on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, today reported results for the three months and full year ended December 31, 2025.

24.02.2026

Amphastar Announces FDA Approval for Ipratropium Bromide HFA

RANCHO CUCAMONGA, CA / ACCESS Newswire / February 24, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for Ipratropium Bromide HFA Inhalation Aerosol 17mcg/actuation. The FDA determined that Amphastar's Ipratropium Bromide HFA Inhalation Aerosol is bioequivalent and therapeutically equivalent to Boehringer Ingelheim's Atrovent® HFA Inhalation Aerosol.

12.01.2026

Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound

Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA / ACCESS Newswire / January 12, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that it has entered into an exclusive license agreement (the "Agreement") with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. ("Hanxin") for the development, and commercialization of a fully synthetic and highly purified human adrenocorticotropic hormone (ACTH) analogs (also termed corticotropin), now designated AMP-110, in the United States and Canada.

Amphastar Pharmaceuticals, Inc. (AMPH)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Amphastar Pharmaceuticals, Inc. (AMPH)

Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2026 Earnings Call Transcript

Compared to Estimates, Amphastar (AMPH) Q1 Earnings: A Look at Key Metrics

Amphastar Pharmaceuticals (AMPH) Q1 Earnings Lag Estimates

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026

Amphastar Pharmaceuticals to Present at the 2026 Bank of America Health Care Conference

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7, 2026

AMPH vs. RDY: Which Stock Should Value Investors Buy Now?

Videos

No Data

Press releases

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025

Amphastar Announces FDA Approval for Ipratropium Bromide HFA

Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound

Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2026 Earnings Call Transcript

Compared to Estimates, Amphastar (AMPH) Q1 Earnings: A Look at Key Metrics

Amphastar Pharmaceuticals (AMPH) Q1 Earnings Lag Estimates

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026

Amphastar Pharmaceuticals to Present at the 2026 Bank of America Health Care Conference

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7, 2026

AMPH vs. RDY: Which Stock Should Value Investors Buy Now?

Videos

No Data

Press releases

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025

Amphastar Announces FDA Approval for Ipratropium Bromide HFA

Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound

Search stocks

Amphastar Pharmaceuticals, Inc. (AMPH)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Amphastar Pharmaceuticals, Inc. (AMPH)

Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2026 Earnings Call Transcript

Compared to Estimates, Amphastar (AMPH) Q1 Earnings: A Look at Key Metrics

Amphastar Pharmaceuticals (AMPH) Q1 Earnings Lag Estimates

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026

Amphastar Pharmaceuticals to Present at the 2026 Bank of America Health Care Conference

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7, 2026

AMPH vs. RDY: Which Stock Should Value Investors Buy Now?

Videos

No Data

Press releases

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025

Amphastar Announces FDA Approval for Ipratropium Bromide HFA

Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound

Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2026 Earnings Call Transcript

Compared to Estimates, Amphastar (AMPH) Q1 Earnings: A Look at Key Metrics

Amphastar Pharmaceuticals (AMPH) Q1 Earnings Lag Estimates

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026

Amphastar Pharmaceuticals to Present at the 2026 Bank of America Health Care Conference

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7, 2026

AMPH vs. RDY: Which Stock Should Value Investors Buy Now?

Videos

No Data

Press releases

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025

Amphastar Announces FDA Approval for Ipratropium Bromide HFA

Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound